China Medical System Holdings secures regulatory approval in Singapore for its vitiligo treatment cream. The company develops and markets dermatological products targeting skin conditions. This marks a key expansion into Southeast Asia’s pharmaceutical market.
China Medical System Holdings adjusts its interim dividend payout for the first half of 2026. The company provides an update on financial distributions to shareholders through its listed holding structure on the Hong Kong Stock Exchange.
China Medical System Holdings gains exclusive distribution rights for critical ophthalmic medications in China. The agreement expands the company’s presence in the domestic pharmaceutical market, targeting eye-care treatments. No specific drugs or financial terms are disclosed in the update.
China Medical System Holdings secures regulatory approval to begin clinical trials for its MG-K10 device targeting chronic obstructive pulmonary disease (COPD). The company’s product aims to address unmet needs in respiratory care, though specific trial details remain undisclosed.
